The Drug Industry Has a 90% Failure Rate. This Company Simulates the Human Body to Fix It.

Nine out of ten drugs fail.

Not in early lab experiments. Not in petri dishes. In human clinical trials — after years of development and hundreds of millions of dollars have already been spent.

That number has barely moved in decades. And the reason is almost embarrassingly straightforward: until very recently, there was no reliable way to know how a drug would behave inside an actual human body before you put it inside an actual human body.

A new approach called whole-body in silico simulation is trying to change that entirely.

The Problem With How Drugs Are Currently Tested

The traditional drug development pipeline works roughly like this: scientists identify a disease target, develop a molecule that might affect it, test it in isolated cells, test it in animals, and then — after three to six years and around $318 million in pre-clinical costs alone — find out whether it actually works in humans.

Most of the time, it doesn't.

The failures are rarely random. They tend to cluster around the same issues: unexpected toxicity (the drug works on its intended target but causes damage somewhere else in the body), poor efficacy in humans despite promising animal results, or off-target effects nobody modeled for because nobody had a complete enough picture of human biology to model against.

The industry has known this for years. The standard response has been incremental — better animal models, more sophisticated cell assays, earlier biomarker testing. None of it has meaningfully moved the 90% attrition needle.

Simulating the Whole Human Body — Before Any Trial

The approach that's starting to turn heads works differently at a foundational level. Instead of testing a molecule against isolated targets, it maps the effects of that molecule against a complete, simulated model of human biology — every relevant biochemical pathway, every organ system interaction, every potential off-target effect — all at once.

The technical term is whole-body in silico simulation. In plain English: a digital human that reacts to drugs the way real humans do, running at computational speed.

One platform doing this compresses the pre-clinical timeline from three to six years down to ten to eighteen months. Pre-clinical costs drop from approximately $318 million to under $2 million. The platform delivers 91% specificity on negative activations and 86% sensitivity on positive activations.

For context: the industry average Phase 1 success rate is 7.9%. Their reported rate is greater than 80%.

What the AI Report Actually Does

Think of it as a credit score for your drug pipeline.

Before you commit a dollar to clinical trial design, the platform generates a comprehensive risk assessment of your candidate molecule. It models target engagement, flags non-obvious toxicities, identifies off-target reactivities, and surfaces adverse biological events that wouldn't show up until Phase 1 or later.

The report is disease-agnostic — oncology, neurology, metabolic disease, rare conditions, it doesn't matter. The simulation engine maps against whole-body human biochemistry, not narrow disease-specific models.

This also opens up drug repurposing: existing approved compounds tested against new targets in simulation, without burning core R&D budget to find out if the hypothesis holds.

Why Patent Timing Makes This a Business Imperative

There's a financial dimension to this that often gets overlooked in the technical conversation.

Drug patents typically run 20 years from filing. Most of that clock ticks while the drug is still in development. By the time a drug reaches the market, the average remaining patent life is around 12 years — sometimes less.

Cutting pre-clinical timelines from six years to eighteen months doesn't just reduce costs. It hands back years of patent-protected market exclusivity. That translates directly into revenue that would otherwise have been burned in development or lost to patent expiry.

Faster de-risking is not just a scientific improvement. It's a compounding financial advantage.

The Shift That's Happening

Drug development has always been a high-stakes bet made with incomplete information. The bet has stayed roughly the same size for decades — the information just wasn't available to reduce it.

That's what's changing. Whole-body simulation doesn't eliminate risk. But it converts unknown risk into known risk, before the capital is committed. For an industry where a single late-stage failure can cost over a billion dollars, that's not a marginal improvement.

It's a structural change in how the game is played.

---

Adam Silva covers the infrastructure shifts reshaping enterprise technology, deep tech, and emerging science. Adam Silva Consulting helps businesses position themselves at the leading edge of what's next.